scispace - formally typeset
A

Anne Lise Børresen-Dale

Researcher at Oslo University Hospital

Publications -  470
Citations -  94317

Anne Lise Børresen-Dale is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 104, co-authored 456 publications receiving 83276 citations. Previous affiliations of Anne Lise Børresen-Dale include University of Oslo & Vanderbilt University.

Papers
More filters
Journal ArticleDOI

Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer

TL;DR: These data demonstrate for the first time that profiling of microRNAs in TIF can identify novel biomarkers for the prognostic classification and detection of breast cancer and demonstrate that micro RNAs may represent the cross‐talk that occurs between tumor cells and their surrounding stroma.
Journal ArticleDOI

Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.

TL;DR: The frequency and prognostic impact of TP53 alterations stratified for the TP53 codon 72 polymorphism in tumor DNA gave a higher frequency of homozygosity/hemizygosity than expected from the population frequency, particularly for the Pro allele.
Journal ArticleDOI

TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas

TL;DR: The results indicate that TP53 abnormalities play a crucial role, and MDM2 abnormalities a minor role, in the development of early‐stage ovarian carcinoma.

Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair

Felix R. Day, +240 more
Journal ArticleDOI

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy

TL;DR: The finding that a high mitotic frequency, as well as a high Ki-67 staining, correlated to TP53 mutations, suggests TP 53 mutations are the key predictor of drug resistance, although cell proliferation may play an additional role in tumours harbouring wild-type TP53.